Epigenetic regulation of programmed genome instability in O. trifallax

三法螟编程基因组不稳定性的表观遗传调控

基本信息

  • 批准号:
    8397434
  • 负责人:
  • 金额:
    $ 5.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-01 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cytosine methylation of DNA is a repressive chromatin mark important for silencing genes during mammalian development, and cancer cells frequently silence tumor suppressor genes by aberrantly methylating their promoters. Genome stability is compromised when DNA methylation patterns are disrupted in cancer or in developmental disease. Despite the critical role of DNA methylation in gene expression and genome stability, the mechanisms guiding de novo DNA methylation remain poorly defined. Oxytricha trifallax is a unicellular eukaryote that performs dramatic genome rearrangements in a developmental process that transforms its micronucleus (MIC) genome into a differentiated macronucleus (MAC). This process is accomplished by the precise elimination of 95% of the genome, and recapitulates the key property of stem cells: self-renewal (one copy of the MIC is retained at all times) and differentiation (MAC formation). Interestingly, my work in the Landweber lab has shown that this organism uses de novo DNA methylation in the elimination process. The fact that most of the Oxytricha genome is methylated and eliminated makes it an attractive model system to understand how methylation is targeted: aberrant methylation and subsequent elimination of the 5% retained DNA would be fatal. In addition, the reproducibility of genome rearrangements in this ciliate makes it a unique model for studying the connection between DNA methylation and genome stability, both of which are relevant to cancer and developmental processes generally. AIM 1: Test the hypothesis that methylation induces DNA degradation in Oxytricha through microinjection of artificially constructed, in vitro methylated chromosomes into the MAC of vegetative cells. AIM 2: Methyl-DNA immunoprecipitation and high throughput sequencing (meDIP-Seq) will be used to define the endogenous domains of de novo DNA methylation during genome rearrangements in Oxytricha. AIM 3: The functional relevance of cytosine methylation in Oxytricha genome rearrangements will be analyzed by use of chemical inhibitors of methyltransferases, followed by deep sequencing the DNA from treated cells. AIM 4: Identification of novel methylation pathway proteins by methyl-cytosine chromatin IP (me-ChIP) and mass-spec analysis. Oxytricha trifallax provides an unprecedented opportunity to study the role of DNA methylation in a model system that has evolved an elaborate genome rearrangement process. Currently, the targeting of de novo methylation in human disease is poorly understood, so insights from Oxytricha will be immediately relevant to studies of human health and disease. Any conserved candidate proteins or motifs identified in the ciliate model can be tested in human tissue culture or mouse cancer models for potential oncogenic roles. PUBLIC HEALTH RELEVANCE: Aberrant DNA methylation causes several human developmental diseases and is correlated with genome instability, cancer initiation, and oncogenic progression. However the mechanism by which DNA methylation is targeted to the correct sequences remains obscure. The goal of the proposed research is to use the unique properties of ciliates to uncover new targets for therapeutic drug development. Ultimately, the ability to correct errors of DNA methylation will allow us to prevent or treat human disease.
描述(由申请人提供):DNA的胞嘧啶甲基化是一种抑制染色质标记,对哺乳动物发育过程中的基因沉默很重要,癌细胞经常通过异常甲基化其启动子来沉默肿瘤抑制基因。当DNA甲基化模式在癌症或发育性疾病中被破坏时,基因组的稳定性就会受到损害。尽管DNA甲基化在基因表达和基因组稳定性中起着关键作用,但指导从头DNA甲基化的机制仍然不明确。三叶草氧tricha trifallax是一种单细胞真核生物,在其微核(MIC)基因组向分化大核(MAC)转变的发育过程中进行了戏剧性的基因组重排。这个过程是通过精确地消除95%的基因组来完成的,并概括了干细胞的关键特性:自我更新(始终保留一个MIC拷贝)和分化(MAC形成)。有趣的是,我在兰德韦伯实验室的工作表明,这种生物体在消除过程中使用了从头DNA甲基化。大多数Oxytricha基因组被甲基化和消除的事实使其成为一个有吸引力的模型系统,以了解甲基化是如何靶向的:异常甲基化和随后的5%保留DNA的消除将是致命的。此外,这种纤毛虫基因组重排的可重复性使其成为研究DNA甲基化与基因组稳定性之间关系的独特模型,这两者通常与癌症和发育过程有关。目的1:通过将人工构建的体外甲基化染色体微注射到营养细胞的MAC中,验证甲基化诱导氧化毛霉DNA降解的假设。目的2:甲基DNA免疫沉淀和高通量测序(meDIP-Seq)将用于确定Oxytricha基因组重排过程中从头DNA甲基化的内源性结构域。目的3:利用甲基转移酶的化学抑制剂分析胞嘧啶甲基化在氧化毛霉基因组重排中的功能相关性,然后对处理细胞的DNA进行深度测序。目的4:通过甲基胞嘧啶染色质IP (me-ChIP)和质谱分析鉴定新的甲基化途径蛋白。三叶草提供了一个前所未有的机会来研究DNA甲基化在一个模型系统中的作用,这个模型系统已经进化出了一个复杂的基因组重排过程。目前,人们对人类疾病中新生甲基化的靶向性知之甚少,因此来自Oxytricha的见解将立即与人类健康和疾病的研究相关。在纤毛虫模型中发现的任何保守的候选蛋白或基序都可以在人类组织培养或小鼠癌症模型中测试潜在的致癌作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Russell Bracht其他文献

John Russell Bracht的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Russell Bracht', 18)}}的其他基金

Expanding high-impact mentorship and research in the Bracht Laboratory
扩大布拉赫特实验室的高影响力指导和研究
  • 批准号:
    10792325
  • 财政年份:
    2022
  • 资助金额:
    $ 5.22万
  • 项目类别:
Investigating the molecular basis of evolved stress resilience in a subterrestrial nematode
研究地下线虫进化的应激恢复能力的分子基础
  • 批准号:
    10438979
  • 财政年份:
    2022
  • 资助金额:
    $ 5.22万
  • 项目类别:
Acquisition of an Oxford Nanopore sequencer for genomic analysis of a subterrestrial nematode
购买牛津纳米孔测序仪用于地下线虫的基因组分析
  • 批准号:
    10797580
  • 财政年份:
    2022
  • 资助金额:
    $ 5.22万
  • 项目类别:
Model systems for the investigation of DNA methylation and drug repurposing
用于研究 DNA 甲基化和药物再利用的模型系统
  • 批准号:
    8679870
  • 财政年份:
    2014
  • 资助金额:
    $ 5.22万
  • 项目类别:
Model systems for the investigation of DNA methylation and drug repurposing
用于研究 DNA 甲基化和药物再利用的模型系统
  • 批准号:
    9131688
  • 财政年份:
    2014
  • 资助金额:
    $ 5.22万
  • 项目类别:
Epigenetic regulation of programmed genome instability in O. trifallax
三法螟编程基因组不稳定性的表观遗传调控
  • 批准号:
    8607867
  • 财政年份:
    2012
  • 资助金额:
    $ 5.22万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了